Naltrexone for Individuals of East Asian Descent

Completed · Phase 2 · Has a placebo group

Conditions studied: Alcohol Use Disorder

In brief

This study will elucidate the pharmacogenetic effects of the Asn40Asp SNP of the OPRM1 gene on biobehavioral and neural markers of response to naltrexone in individuals of East Asian descent, an ethnic group most likely to express the positive predictive allele.

Key facts

Study ID

NCT02026011

Run by

University of California, Los Angeles

People needed

87

Starts

2013-12-01

Expected to finish

2016-09-01

Last updated by the study team

2019-07-17

Who can join

Age: 21 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• current (i.e., past month) alcohol dependence
• East Asian ethnicity (i.e., Chinese, Korean, or Japanese)
• Prospective genotyping for the A118G SNP of the mu opioid receptor (OPRM1) gene to allow for balanced groups on all three genotypes (AA, AG, GG)

You may not qualify if…

• lifetime DSM-IV of drug dependence (other than alcohol or nicotine)
• current use of psychoactive drugs as determined by self-reports and verified using toxicology testing
• lifetime diagnosis of bipolar disorder or any psychotic disorder
• contraindications to an MRI scan (including left handedness)

Where it is running

• UCLA Addictions Laboratory — Los Angeles, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.